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Asian bats have been identiﬁ  ed as potential reservoir 
hosts of coronaviruses associated with severe acute respira-
tory syndrome (SARS-CoV). We detected antibody reactive 
with SARS-CoV antigen in 47 (6.7%) of 705 bat serum speci-
mens comprising 26 species collected in Africa; thus, African 
bats may harbor agents related to putative group 4 CoV.
S
evere acute respiratory syndrome (SARS) emerged 
as a newly recognized human disease in the People’s 
Republic of China late in 2002 and spread globally, caus-
ing 8,422 infections with 916 (11%) deaths before it was 
brought under control in 2003 (1). The causative agent was 
identiﬁ  ed as a coronavirus (SARS-CoV) (2–4), and related 
viruses found in palm civets (Paguma larvata), raccoon 
dogs (Nycereutes procyonoides) (5), and insectivorous bats 
in Asia cluster phylogenetically together with SARS-CoV 
in a putative group 4 (6–10). Farmed food animals such 
as civets may acquire SARS-like-CoV infection from bats, 
and adaptation of the viruses to these secondary hosts may 
occasionally give rise to strains capable of spreading and 
causing disease in humans (HCoV) (10).
The Study
Bat serum specimens (n = 705) collected from 1986 
through 1999 in South Africa (SA) and the Democratic Re-
public of the Congo (DRC) were tested. The ﬁ  rst 248 se-
rum specimens were collected from 1986 through 1989 in 
the Mpumalanga and Limpopo Provinces of SA for studies 
on rabies-related viruses, with the approval of the provin-
cial Directorates of Nature Conservation and the Animal 
Ethics Committee of the University of the Witwatersrand. 
The remaining 457 serum samples were collected in 
1995–1999 in the Bandundu and Oriental Provinces of the 
DRC for studies on Ebola and Marburg viruses, under the 
auspices of the International Committees for the Control 
of Ebola hemorrhagic  fever  in Kikwit, and Marburg hem-
orrhagic fever in Durba-Watsa, coordinated by the World 
Health Organization on behalf of the government of DRC. 
Bats were caught in mist nets, anesthetized, and exsangui-
nated by cardiac puncture. Serum specimens were stored at 
–70°C until analyzed.
For screening of serum specimens we used the SARS-
CoV ELISA kit (EUROIMMUN AG, Lübeck, Germany) 
with minor modiﬁ  cations. Bat serum samples were tested at 
a dilution of 1:50, and horseradish peroxidase–labeled goat 
antibat immunoglobulin (Ig) conjugate (Bethyl, Montgom-
ery, AL, USA) was used as secondary antibody at a dilution 
of 1:2,000. Negative bat serum was obtained from a cap-
tive-bred Rousettus aegyptiacus at the National Institute 
for Communicable Diseases, Sandringham, SA. The cut-
off was determined as 3× the mean optical density value at 
450/605 nm observed in negative control samples. Positive 
serum samples were retested and their titers determined. 
To evaluate test speciﬁ  city and to exclude possible cross-
reactivity to other viruses, especially to HCoVs, which 
have a seroprevalence in humans >90% (11), 662 human 
serum specimens were screened (online Technical Appen-
dix, available from www.cdc.gov/EID/content/13/9/1367-
Techapp.htm), including those from 90 patients with other 
acute respiratory infections, 70 HCoV-229E–positive se-
rum specimens and 4 HCoV-NL63–positive serum speci-
mens (provided by L. van der Hoek).
A conﬁ  rmatory Western blot (WB) was done by us-
ing protein lysates from Vero E6 cell cultures (American 
Type Culture Collection [Manassas, VA, USA] CRL 1586) 
infected with SARS-CoV Hong Kong isolate 6109 (Gen-
Bank accession no. AY278491) and from uninfected Vero 
E6 cultures. Bat serum specimens were applied at dilutions 
of 1:500 and 1:2,000. Secondary detection was performed 
with the SuperSignal West Dura Extended Substrate che-
miluminescence detection assay (Pierce Biotechnology, 
Rockford, IL, USA). The signal intensity of the 150-kDa 
spike (S), 50-kDa nucleocapsid (N) proteins was evaluated 
independently by 2 operators. For a second conﬁ  rmatory 
WB, recombinant SARS-CoV proteins were used. For pro-
karyotic expression of recombinant SARS-CoV N protein 
and a fragment of the S protein (amino acid positions 318–
510), we followed the instructions of the Champion pET 
Directional TOPO Expression kit (Invitrogen, Karlsruhe, 
Germany) using plasmids pET101-N and pET102-Saa318–
510. Puriﬁ  cation and refolding of the protein on column 
were done as described previously (12). Puriﬁ  ed recombi-
nant protein (15 μg) was resolved by electrophoresis on a 
discontinuous 12% sodium dodecyl sulfate–polyacrylamide 
gel. After blotting, nitrocellulose strips were incubated with 
bat serum samples diluted 1:2,500 and 1:5,000. One posi-
tive bat serum specimen was used as a reference to exclude 
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variations in experimental procedures and signal intensi-
ties. Serum specimens that produced signals at a dilution 
1:5,000 were considered positive as none of the control se-
rum specimens showed reactivity at that dilution. To evalu-
ate assay speciﬁ  city, we tested 19 control serum specimens 
comprising 12 randomly selected bat serum specimens that 
were negative by ELISA, 2 SARS-CoV–positive human 
serum specimens, and 5 SARS-CoV–negative human se-
rum specimens, including 4 HCoV-NL63–positive serum 
specimens.
A commercial indirect immunoﬂ  uorescence  test 
(SARS-CoV-IFTII kit, EUROIMMUN AG) was carried 
out as described by the manufacturer, except that bat se-
rum samples were diluted 1:100, and slides were incubated 
at room temperature for 2 hours. Reactions were detected 
with goat-antibat immunogolublin (Ig) (Bethyl) at a dilu-
tion of 1:1,000 and ﬂ  uorescein isothiocyanate–labeled don-
key-antigoat Ig (Dianova, Hamburg, Germany) at a dilution 
of 1:100. Speciﬁ  city of the indirect immunoﬂ  uorescence 
test (IIFT) was determined by screening 572 human serum 
specimens. The sensitivity and correlation of IIFT versus 
ELISA were analyzed (online Technical Appendix). In ad-
dition, the 19 selected control serum samples were tested.
Virus neutralization tests were performed as described 
elsewhere (13) except for using Vero E6 cells cultured in 
Dulbecco’s modiﬁ  ed Eagle medium and SARS-CoV Hong 
Kong isolate 6109 (3.25 × 107 PFU/mL, diluted 1:5,000). 
Bat serum dilutions in quadruplicate ranged from 1:10 to 
Table. Antibody to SARS-CoV in bat sera collected in 1986–1999 at 4 locations in central and southern Africa* 
ELISA: positive/tested (%)†
Limpopo
Province, SA
Mpumalanga
Province, SA
Oriental
Province, DRC
Bandundu
Province, DRC Total
WB:
positive/
tested‡
IIFT:
positive/
tested‡
Fruit bats
 Casinycteris  argynnis 0/3 0/3
 Eidolon  helvum 0/6 0/6
 Epomophorus  gambianus 0/4 0/6 0/10
 Epomophorus  wahlbergi 0/2 0/2
 Epomops  franqueti 0/5 0/5
 Hypsignathus  monstrosus 1/11
(9.1)
1/11
(9.1)
1/1 0/1
 Lyssonycteris  angolensis 1/16
(6.3)
0/2 1/18
(5.6)
1/1 0/1
 Myonycteris  torquata 1/7
(14.3)
1/7
(14.3)
 Rousettus  aegyptiacus 11/29
(37.9)
17/142
(12.0)
28/171  
(16.4)
26/26 7/26
Insect bats
 Chaerephon  pumila 0/35 0/18 0/1 0/54
 Hipposideros  caffer 0/5 0/9 0/15
 Hipposideros  commersoni 0/16 0/16
 Miniopterus  inflatus 1/34
(2.9)
1/34  
(2.9)
 Miniopterus  schreibersi 0/1 0/1
 Mops  condylurus 3/19
(15.8)
11/96
(11.5)
14/115
(12.2)
8/9 5/9
 Mops  midas 0/15 0/15
 Myotis  bocagei 0/1 0/1
 Nycteris  argae 0/1 0/1
 N.  thebaica 0/6 0/6
 Pipistrellus  capensis 0/1 0/1
 Rhinolophus  darlingi 0/1 0/1
 Rhinolophus  landeri 0/2 0/2
 Rhinolophus  fumigatus 1/204
(0.5)
1/204  
(0.5)
 Scotophilus  borbonicus 0/1 0/1
 S.  dinganii 0/5 0/5
 Taphozous  mauritianus 0/1 0/1
Totals 14/128
(10.9)
11/120
(9.2)
20/422
(4.7)
2/35
(5.7)
47/705
(6.7)
36/37 12/37
*SARS-CoV, severe acute respiratory syndrome–associated coronavirus; SA, South Africa; DRC, Democratic Republic of Congo; WB, Western blot; IIFT, 
indirect immunofluorescence test. 
†Serum specimens were screened for antibody by modification of a commercially available ELISA kit. Titers ranged from 1:50 to 1:800. 
‡Confirmatory tests were performed by 2 WB analyses and IIFT when sufficient sample was available. Coronavirus Antibodies in African Bats
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1:320. After incubation at 37°C in 5% CO2 for 3 days, the 
cells were ﬁ  xed with 8% formaldehyde and results inter-
preted as described (13).
Viral RNA was extracted from serum by using a 
QIAamp viral RNA extraction kit (QIAGEN, Hilden, Ger-
many), and reverse transcription–PCR (RT-PCR) was per-
formed essentially as described elsewhere (14), with the 
exception that 140 μL was not available from every bat. 
In such cases, input volume was reduced and replaced with 
water. A minimum of 20 μL was usually tested. 
Antibody activity to SARS-CoV antigen was detected 
by ELISA in 7 of 26 bat species tested at both collection 
sites with a seroprevalence of 6.7% (47/705). The highest 
prevalences were found in the fruit bat Rousettus aegyp-
tiacus (Chiroptera: Pteropodidae) (16.4%) and the insec-
tivorous bat Mops condylurus (Chiroptera: Molossidae) 
(12.2%) (Table). ELISA titers ranged from 50 (73% of 
the serum samples) to 800. Conﬁ   rmatory WB analyses 
performed by 2 methods on ELISA-positive samples for 
which sufﬁ  cient material remained available, were positive 
in 36 (97.3%) of 37 serum specimens, but IIFT was posi-
tive in only 12 (32.4%) of 37 samples (Table; Figures 1, 
2; Figure in online Technical Appendix). None of the as-
says used detected antibodies to other human pathogenic 
coronaviruses (online Technical Appendix; Figures 1, 2). 
Neutralizing activity to SARS-CoV was not found in any 
of the ELISA-positive samples, and RT-PCR did not detect 
CoV nucleic acid in 262 serum specimens tested (data not 
shown).
Conclusions
The results of WB analyses support the speciﬁ  city of 
the ELISA used in this study. The IF test is known to be 
less sensitive than ELISA but still provided conﬁ  rmation in 
one third of the serum specimens tested. The negative re-
sults in the viral neutralization tests are not unexpected be-
cause this assay detects only antibodies that interfere with 
the speciﬁ  c entry mechanism of SARS-CoV, and putative 
group 4 CoVs from African bats may not use it. Moreover, 
deletions and mutations found in Asian bat SARS-like–CoV 
isolates lie in the S protein region essential for binding of 
SARS-CoV to the cellular receptor, angiotensin-convert-
ing enzyme 2, and thus are likely to affect cross-neutraliza-
tion, as emphasized by conﬂ  icting results obtained in Asia 
(6,7,15). The negative ﬁ  ndings obtained in RT-PCR can 
be explained by the unlikelihood of ﬁ  nding virus nucleic 
acid in serum. Studies in Asia used rectal swabs instead of 
serum samples, and the virus likely persists in the enteric 
tract but may not be found in serum at all.
Both bat species (R. aegyptiacus and M. condylurus) 
are widely distributed in Africa but vary in the degree of 
contact with humans. R. aegyptiacus roosts in caves but 
forages in orchards, whereas M. condylurus roosts in build-
ings. The results of this preliminary study suggest that some 
Figure 1. Results of Western blot analysis with recombinant severe 
acute respiratory syndrome–associated coronavirus (SARS-CoV) 
nucleocapsid (N) and spike (S) protein. Shown are examples for 
SARS-CoV ELISA–positive (2, 17, 26, 31) and –negative (38, 321) 
bat serum specimens tested using full-length recombinant SARS-
CoV N and a fragment of the S protein (amino acids 318–510). 
Serum specimens were diluted 1:2,500 (left strips) and 1:5,000 
(right strips). Secondary detection was performed by incubating 
the nitrocellulose strips with horseradish peroxidase (HRP)–
labeled goat-antibat immunoglobulin (Ig) (Bethyl, Montgomery, 
AL, USA) (1:10,000). For chemiluminescence, SuperSignal Dura 
substrate (Pierce Biotechnology, Rockford, IL, USA) was added 
and ﬁ  lms exposed for 1 min. Serum 17* was used as a reference 
for comparing blots. For evaluation purposes, strips were also 
incubated with human SARS-CoV–positive (A, B) and –negative 
serum specimens C and D (HCoV-NL63 positive) at the same 
dilutions, using goat-antihuman Ig HRP (1:20,000) for secondary 
detection. Serum specimens that produced signals at a dilution of 
1:5,000 were recorded as positive (+). 
Figure 2. Results of indirect immunoﬂ  uorescence test (IIFT) with 
Vero E6 cells infected with severe acute respiratory syndrome–
associated coronavirus (SARS-CoV). The SARS-CoV diagnostic 
IIFT kit (EUROIMMUN AG, Lübeck, Germany) was used with 
minor modiﬁ  cations: bat and reference human serum specimens 
were diluted 1:100 (found to be the optimal dilution for bat sera) 
in sample buffer, and secondary detection was performed with 
goat-antibat immunoglobulin (Ig) (Bethyl, Montgomery, AL, USA) 
followed by ﬂ   uorescein isothiocyanate (FITC)–labeled donkey-
antigoat Ig (Dianova, Hamburg, Germany) (A–F) or FITC-labeled 
goat-antihuman Ig (G–I). Frames A–D, SARS-CoV ELISA–positive 
bat serum specimens 2, 17, 26, 31; E–F, ELISA-negative bat 
serum specimens 38 (showing unspeciﬁ  c signals) and 306; G–H, 
SARS-CoV–positive human control serum specimens A and B; I, 
negative human serum C. All photographs were taken at equivalent 
microscope settings. Scale bars represent 20 μm. DISPATCHES
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of the African bat species harbor agents related to putative 
group 4 CoV, and therefore further investigations should be 
undertaken to determine potential public health risks.
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